Effect	O
of	O
Fusarium	B:C0016871
-	O
Derived	O
Metabolites	B:C0870883
on	O
the	O
Barrier	O
Integrity	O
of	O
Differentiated	O
Intestinal	B:C0021853
Porcine	B:C0039005
Epithelial	B:C0014597
Cells	I:C0014597
(	O
IPEC	B:C0014597
-	I:C0014597
J2	I:C0014597
)	O
.	O

The	O
human	B:C0086418
,	O
animal	B:C0003062
and	O
plant	B:C0032098
pathogen	B:C0016871
Fusarium	I:C0016871
,	O
which	O
contaminates	O
agricultural	B:C0242775
commodities	I:C0242775
worldwide	O
,	O
produces	O
numerous	O
secondary	B:C0870883
metabolites	I:C0870883
.	O

An	O
example	O
is	O
the	O
thoroughly	O
-	O
investigated	O
deoxynivalenol	B:C0057445
(	O
deoxynivalenol	B:C0057445
)	O
,	O
which	O
severely	O
impairs	O
gastrointestinal	B:C0521362
barrier	O
integrity	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
toxicological	B:C0852616
profile	I:C0852616
of	O
other	O
Fusarium	B:C0016871
-	O
derived	O
metabolites	B:C0870883
,	O
such	O
as	O
enniatins	B:C0059362
,	O
beauvericin	B:C0053065
,	O
moniliformin	B:C0066713
,	O
apicidin	B:C0531691
,	O
aurofusarin	B:C0661658
,	O
rubrofusarin	B:C0084424
,	O
equisetin	B:C0059495
and	O
bikaverin	B:C0053576
,	O
are	O
poorly	O
characterized	O
.	O

Thus	O
we	O
examined	O
their	O
effects	O
-	O
as	O
metabolites	B:C0870883
alone	O
and	O
as	O
metabolites	B:C0870883
in	O
combination	O
with	O
deoxynivalenol	B:C0057445
-	O
on	O
the	O
intestinal	O
barrier	O
function	O
of	O
differentiated	O
intestinal	B:C0021853
porcine	B:C0039005
epithelial	B:C0014597
cells	I:C0014597
(	O
IPEC	B:C0014597
-	I:C0014597
J2	I:C0014597
)	O
over	O
72	O
h.	O

Transepithelial	B:C2753390
electrical	O
resistance	O
(	O
TEER	O
)	O
was	O
measured	O
at	O
24-h	O
intervals	O
,	O
followed	O
by	O
evaluation	O
of	O
cell	B:C1516362
viability	I:C1516362
using	O
neutral	B:C1293998
red	I:C1293998
(	I:C1293998
NR	I:C1293998
)	I:C1293998
assay	I:C1293998
.	O

Enniatins	B:C0116182
A	I:C0116182
,	O
A1	B:C0059362
,	O
B	B:C0116183
and	O
B1	B:C0059362
,	O
apicidin	B:C0531691
,	O
aurofusarin	B:C0661658
and	O
beauvericin	B:C0053065
significantly	O
reduced	O
TEER	O
.	O

Moniliformin	B:C0066713
,	O
equisetin	B:C0059495
,	O
bikaverin	B:C0053576
and	O
rubrofusarin	B:C0084424
had	O
no	O
effect	O
on	O
TEER	O
.	O

In	O
the	O
case	O
of	O
apicidin	B:C0531691
,	O
aurofusarin	B:C0661658
and	O
beauvericin	B:C0053065
,	O
TEER	O
reductions	O
were	O
further	O
substantiated	O
by	O
the	O
addition	O
of	O
otherwise	O
no-effect	O
deoxynivalenol	B:C0057445
concentrations	O
.	O

In	O
all	O
cases	O
,	O
viability	B:C1516362
was	O
unaffected	O
,	O
confirming	O
that	O
TEER	O
reductions	O
were	O
not	O
due	O
to	O
compromised	O
viability	B:C1516362
.	O

Considering	O
the	O
prevalence	O
of	O
mycotoxin	B:C0026955
contamination	O
and	O
the	O
diseases	B:C0012634
associated	O
with	O
intestinal	O
barrier	O
disruption	O
,	O
consumption	B:C0559583
of	I:C0559583
contaminated	I:C0559583
food	I:C0559583
or	I:C0559583
feed	I:C0559583
may	O
have	O
substantial	B:C0243095
health	I:C0243095
implications	I:C0243095
.	O

